QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=597341C8321AA7CB23A6FED7FBBFA001;jsessionid=20CF677C5CA9F69025FA32B0252B15CE;jsessionid=6D113F22F44525B441FDFA8029FFEBE5;jsessionid=CCBD7430C8A5493F549F414D345B1F0B;jsessionid=30F87114A1F2BF0477FB6C32363E2A9E;jsessionid=10096D2E69228CFDD613510C18206836 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=597341C8321AA7CB23A6FED7FBBFA001;jsessionid=20CF677C5CA9F69025FA32B0252B15CE;jsessionid=6D113F22F44525B441FDFA8029FFEBE5;jsessionid=CCBD7430C8A5493F549F414D345B1F0B;jsessionid=30F87114A1F2BF0477FB6C32363E2A9E;jsessionid=10096D2E69228CFDD613510C18206836